3.33
-2.06%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Inventiva
Its shares trade on Euronext Paris under the ticker IVA.PA. It has been listed since 15 February 2017. In the fiscal year to 31 December 2025, it reported revenue of €4.5m and a net loss of €354.1m. At that date it held total assets of €249.5m and shareholders' equity of −€28.5m.
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Feb 2017
- Employees
- 88
- Website
- inventivapharma.com ↗
Leadership
Pay as last reported
- Dr. Mark PruzanskiChairman of the Board
- Mr. Andrew ObenshainChief Executive Officer, Director, since 2025
- Mr. Jean VolatierChief Financial Officer, since 2022
- Dr. Jason CampagnaPresident - Research and Development, Chief Medical Officer
- Ms. Alice Roudot-KetelersChief Operating Officer
- Ms. Pascaline ClercExecutive Vice President - Strategy and Corporate Affairs
- Mr. Eric DuransonGeneral Counsel
- Ms. Nathalie HarroyDirector - Human Resources
- Ms. Renee Aguiar-lucanderIndependent Director
- Dr. Srinivas AkkarajuIndependent Director
- Mr. Heinz MaeusliIndependent Director€49,200
- Dr. Annick SchwebigIndependent Director€61,200
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Inventiva SA possesses several key strengths that contribute to its competitiveness in the market:
- Despite its strengths, Inventiva SA also faces certain weaknesses that may hamper its performance:
- Inventiva SA can leverage the following opportunities to further grow and expand its business:
- Inventiva SA faces several external threats that impede its growth and profitability:
Weaknesses
- Despite its strengths, Inventiva SA also faces certain weaknesses that may hamper its performance:
- Inventiva SA can leverage the following opportunities to further grow and expand its business:
- Inventiva SA faces several external threats that impede its growth and profitability:
Opportunities
- Inventiva SA can leverage the following opportunities to further grow and expand its business:
- Inventiva SA faces several external threats that impede its growth and profitability:
Threats
- Inventiva SA faces several external threats that impede its growth and profitability:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.